Results 181 to 190 of about 54,679 (264)

Second-line treatments for patients with programmed cell death protein 1-refractory cutaneous squamous cell carcinomas: a brief report. [PDF]

Oncologist
AlSharif H, Danchine V, Deekollu K, Hasanov M, Wu R, Haykal T, Faieta A, Verschraegen CF.   +7 more
europepmc   +1 more source

Hepatic Arterial Infusion Chemotherapy plus either Toripalimab or Sorafenib as First‐line Therapy for Locally Advanced Hepatocellular Carcinoma: A Non‐comparative, Randomized Phase 2 Trial

MedComm, Volume 7, Issue 6, June 2026.
This phase II study explored the efficacy and safety of HAIC plus toripalimab in locally advanced HCC. The primary endpoint was the PFS rate at 6 months. The 6‐month PFS rate was 63.9% in the TorHAIC group and 61.1% in the SoraHAIC group. Treatment with the TorHAIC regimen resulted in a median OS of 20.9 months and a median PFS of 9.1 months.
Zhicheng Lai, Aojie Ge, Hanyue Ouyang, Zichao Wu, Yexing Huang, Qijiong Li, Li Xu, Binkui Li, Minshan Chen, Dongsheng Wen, Anna Kan, Ming Shi, Minke He   +12 more
wiley   +1 more source

The Tumor Immune Microenvironment in Endometrial Cancer: Composition, Molecular Subtypes, and Therapeutic Implications

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Endometrial cancer (EC), a major gynecologic malignancy and a representative “cold tumor”, exhibits a tumor immune microenvironment (TIME) influenced by a broad range of cellular and molecular elements, immunosuppressive signals, and pathways of immune evasion.
Jingxuan Ye, Yashi Shi, Alexander Mustea, Xiaodan Mao, Pengming Sun   +4 more
wiley   +1 more source

Efficacy and CNS Toxicity of Nivolumab and Ipilimumab in Rare Cancer Brain Metastases: A Multicenter Basket Trial Analysis (NCI/SWOG S1609). [PDF]

Clin Cancer Res
Ahluwalia MS, Solomon S, Patel SP, Sarfraz Z, Othus M, Chae YK, Kurzrock R.   +6 more
europepmc   +1 more source

Sarcomatoid Transformation of Pulmonary Mucinous Adenocarcinoma as a Mechanism of Immunotherapy Resistance

Thoracic Cancer, Volume 17, Issue 12, June 2026.
A patient with a pulmonary invasive mucinous adenocarcinoma (IMA) underwent a histological transformation into sarcomatoid carcinoma with multiple lymph node metastases following long‐term immunochemotherapy. BRAF D594G mutation was detected both at baseline and at the time of recurrence.
Kensuke Yanai, Tomohiro Tanaka, Konomi Kimura, Shinji Hirose, Hiroki Watanabe, Takaaki Masuda, Ryo Suzuki, Kohei Kushiro, Naohiro Yanagimura, Shuhei Kondo, Koichiro Nozaki, Yu Saida, Miyuki Sato, Satoshi Watanabe, Hajime Umezu, Koichi Hagiwara, Toshiaki Kikuchi   +16 more
wiley   +1 more source

Compartment-specific immune and tumor markers associated with clinical outcomes in patients with and without sarcomatoid/rhabdoid renal cell carcinoma treated with ipilimumab and nivolumab. [PDF]

ESMO Open
Savion-Gaiger N, Perales O, Su DG, Bar-Ziv D, Challa P, Djureinovic D, Yi I, Adeniran A, Kluger H, Schoenfeld D.   +9 more
europepmc   +1 more source

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 3, Page 333-350, June 2026.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau   +7 more
wiley   +1 more source

Perioperative immunotherapy for advanced resectable melanoma: a cost-effectiveness analysis. [PDF]

BMC Health Serv Res
Rui M, Wei Q, Wang Y, You JHS.
europepmc   +1 more source

Personalized Cancer Vaccines in the Clinical Trial Pipeline

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 3, Page 362-368, June 2026.
ABSTRACT Aim To present an overview of personalized cancer vaccines currently undergoing clinical development, aiming to enhance awareness and promote collaboration among academic, commercial researchers, and non‐profit communities. Methods A dataset of 78 clinical trials for personalized cancer vaccines was generated using ClinicalTrials.gov database ...
Liudmila Iamukova, Elena Alferova
wiley   +1 more source

Nivolumab rechallenge after pituitary apoplexy associated with nivolumab plus ipilimumab in a patient with pituitary adenoma and rectal melanoma: a case report and literature review. [PDF]

J Pharm Health Care Sci
Imai C, Uchida M, Takahashi K, Ohno I, Takiguchi Y, Ishii I.   +5 more
europepmc   +1 more source